

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/154099>

Please be advised that this information was generated on 2021-06-19 and may be subject to change.

RESEARCH ARTICLE

# The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes Mellitus

Athanasios D. Protogerou<sup>1,2\*</sup>, Jaap Fransen<sup>3</sup>, Evangelia Zampeli<sup>1,2</sup>, Antonis A. Argyris<sup>1</sup>, Evagelia Aissopou<sup>1</sup>, Aikaterini Arida<sup>1,2</sup>, George D. Konstantonis<sup>1,2</sup>, Nikos Tentolouris<sup>1</sup>, Konstantinos Makrilakis<sup>1</sup>, Mina Psychogiou<sup>1</sup>, George Daikos<sup>1</sup>, George D. Kitas<sup>4,5</sup>, Petros P. Sfikakis<sup>1,2</sup>

**1** First Department of Propaedeutic & Internal Medicine, Laikon Hospital, Athens, Greece, **2** Joint Academic Rheumatology Program of the National and Kapodistrian University of Athens Medical School, Athens, Greece, **3** Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, **4** Department of Rheumatology, Dudley Group NHS Foundation Trust, Dudley, United Kingdom, **5** Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom

\* [aprotog@med.uoa.gr](mailto:aprotog@med.uoa.gr)



**OPEN ACCESS**

**Citation:** Protogerou AD, Fransen J, Zampeli E, Argyris AA, Aissopou E, Arida A, et al. (2015) The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes Mellitus. PLoS ONE 10(7): e0132307. doi:10.1371/journal.pone.0132307

**Editor:** Giuseppe Schillaci, University of Perugia, ITALY

**Received:** March 6, 2015

**Accepted:** June 11, 2015

**Published:** July 31, 2015

**Copyright:** © 2015 Protogerou et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All data have been uploaded to Figshare at the following DOI: <http://dx.doi.org/10.6084/m9.figshare.1466738>.

**Funding:** Supported by ELKE grant 097, Athens University Medical School. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No other source of funding exists.

## Abstract

### Background

Presence of femoral atheromatic plaques, an emerging cardiovascular disease (CVD) biomarker additional to carotid plaques, is poorly investigated in conditions associating with accelerated atherosclerosis such as Rheumatoid Arthritis (RA), Human Immunodeficiency Virus (HIV) infection and Type 2 Diabetes Mellitus (T2DM).

### Objective/Methods

To assess the frequency of femoral/carotid subclinical atheromatosis phenotypes in RA, HIV and T2DM and search for each disease-specific probability of either femoral and/or carotid subclinical atheromatosis, we examined by ultrasound a single-center cohort of CVD-free individuals comprised of consecutive non-diabetic patients with RA (n=226) and HIV (n=133), T2DM patients (n=109) and non-diabetic individuals with suspected/known hypertension (n=494) who served as reference group.

### Results

Subclinical atheromatosis - defined as local plaque presence in at least on arterial bed - was diagnosed in 50% of the overall population. Among them, femoral plaques only were found in 25% of either RA or HIV patients, as well as in 16% of T2DM patients and 35% of

**Competing Interests:** The authors have declared that no competing interests exist.

reference subjects. After adjusting for all classical CVD risk factors, RA and HIV patients had comparable probability to reference group of having femoral plaques, but higher probability (1.75; 1.17 - 2.63 (odds ratio; 95% confidence intervals), 2.04; 1.14 - 3.64, respectively) of having carotid plaques, whereas T2DM patients had higher probability to have femoral and carotid plaques, albeit, due to their pronounced dyslipidemic profile.

## Conclusion

RA and HIV accelerate predominantly carotid than femoral. A “two windows” carotid/femoral, rather than carotid alone ultrasound, screening improves substantially subclinical atherosclerosis detection in patients at high CVD risk.

## Introduction

Accelerated carotid atheromatosis has been widely described in the presence of classical cardiovascular disease (CVD) risk factors, as well as in patients with Rheumatoid Arthritis (RA) [1,2], Human Immunodeficiency Virus (HIV) infection [3] and Type 2 Diabetes Mellitus (T2DM) [4]. In these populations, atheromatosis should be regarded as an important pathophysiological mechanism associated to their elevated CVD risk [4,5,6,7]. Subclinical carotid atheromatosis is a predictor of mortality, independently from major classical CVD risk factors, in individuals with hypertension or diabetes [8], those with established CVD [9], as well as in patients with specific diseases such as RA [10] and HIV infection [11]. Thus, carotid plaque presence might serve as a vascular biomarker to optimize CVD risk prediction. Indeed, several recent international guidelines have incorporated carotid ultrasound examination for the optimized reclassification of CVD risk [4,12,13,14,15,16].

Atheromatosis is a pathological process affecting multiple arterial sites, yet in an unpredictable pattern. Most recently, Weir-McCall et al. showed that subclinical carotid atheromatosis does not correlate with global atheromatosis burden [17]. In clinical practice, assessment of subclinical femoral atheromatosis is easy but much less investigated than carotid atheromatosis. Recent data have shown that the combined presence of both carotid and femoral plaques associates more strongly than carotid plaque alone with the incidence of CVD events in low CVD risk individuals [18], in patients with Systemic Sclerosis and Systemic Lupus Erythematosus [19]. Moreover, several lines of evidence suggest that classical CVD risk factors affect differentially atheromatosis in distinct arterial sites (e.g. carotid and femoral arteries)[20]. Therefore, it is important to know whether, by using a “two-windows” (femoral and carotid) subclinical atheromatosis screening approach, we can detect a substantial number of patients in each disease that will have either the unfavorable phenotype of combined femoral and carotid subclinical atheromatosis, or, will have only femoral subclinical atheromatosis that would not be identified by the one window (carotid) screening approach. Although carotid subclinical atheromatosis has been investigated in large cohorts [21], on the contrary, studies investigating both subclinical femoral and carotid atheromatosis especially in the presence of novel CVD risk factors, such as RA disease [22] and HIV infection [23] are scarce.

Based on the above, in the present study we aimed: (a) to assess the frequency of femoral/carotid subclinical atheromatosis phenotypes (i.e. only femoral; only carotid; both femoral and carotid) in patients with RA, HIV infection and T2DM; and (b) to assess the disease-specific probability of either carotid and/or femoral plaque presence, compared to a reference group of non-diabetic individuals with suspected/known hypertension.

## Methods

All participants provided written informed consent according to the World Health Organization statement on ethical principles for medical research involving human subjects developed in Helsinki [24] and the protocol was approved by the “Laiko” Hospital’s institutional review board.

### Study design—Population

Consecutive consenting adult patients with:(i) RA (without T2DM) from the Rheumatology outpatient clinic; (ii) HIV infection (without T2DM) from the HIV outpatient clinic;(iii) T2DM (without any chronic inflammatory or autoimmune disease) from the Diabetes outpatient clinic, were all referred to the Cardiovascular Research Laboratory of our department and included in the study. Moreover, individuals with suspected or diagnosed hypertension (without diabetes and any chronic inflammatory/autoimmune disease)from the Hypertension outpatient clinic were included in the study and comprised the RG. All participants underwent the same vascular investigations. Participants with established CVD (defined as pre-existing coronary artery disease, stroke and peripheral arterial disease), type 1 diabetes mellitus and any other than the predefined chronic diseases were excluded from the analysis, in order to avoid any confounding effect. All RA patients had a clinical diagnosis and met the retrospective application of the American Rheumatism Association 1987 revised criteria [25]. HIV was diagnosed on the basis of the ECDC Guidance HIV testing guidelines [26]. T2DM was diagnosed by use of glucose lowering drugs or abnormal fasting glucose levels  $>125\text{mg/dl}$  in 2 separate occasions and/or  $\text{HbA1c}>6.5\%$  and/or abnormal oral glucose tolerance test [27].

### Arterial ultrasound studies

In this CVD disease-free population, subclinical atherosclerosis was defined as the presence plaque in either the femoral or carotid bed. High-resolution ultrasound was used for the detection of carotid artery and femoral artery plaques in 8 (far and near wall) arterial sites (left and right common carotid, internal carotid arteries and carotid bulb and common femoral artery). Atheromatic plaques were defined as local increase of the intimal-medial thickness of  $>50\%$  compared to the surrounding vessel wall, an intimal-medial thickness  $>1.5\text{ mm}$ , or local thickening  $>0.5\text{ mm}$  [28]. Carotid plaque presence was defined as the presence of plaque in at least 1 of the 6 measured carotid sites. All measurements were performed by the same experienced operator (GD Konstantonis) using a high-resolution B-mode ultrasound device (Vivid 7 Pro, GE Healthcare) with a 14-MHz multi-frequency linear transducer.

### Definition of CVD risk factors

Hypertension was defined by the use of antihypertensive drugs and/or office blood pressure measurement higher than 139/89 (average of 3 sequential readings with 1 min interval in the supine position after at least 10 min of rest (Microlife WatchBP Office, Microlife AG, Widnau, Switzerland). Dyslipidemia was defined on the basis of treatment with lipid modifying drugs or low-density lipoprotein cholesterol level  $>160\text{ mg/dl}$ . Current smoking was defined by the use of at least 1 cigarette per day each day of the week; ex smoking was defined as discontinuation for more than 6 months. Body mass index was calculated as  $\text{weight}/(\text{height}^2)$  ( $\text{kg}/\text{m}^2$ ) and used as a marker of obesity. Family history of premature CVD was defined as the presence of coronary heart disease in a 1st degree relative under the age of 55 years for males and 65 years for females. Required data were retrieved from the medical records of the participants.

### Statistical analysis

Continuous variables are presented as mean±standard deviation and categorical variables as percentage. We used multivariate logistic regression models (with odds ratio and 95% confidence intervals), before and after correcting for the presence of intermediates/confounders, to test the probability in each of the above subgroups of patients (T2DM, RA and HIV infection) to have either carotid or femoral subclinical atheromatosis (plaque presence) using as comparator the RG. The selection of CVD risk factors as potential intermediates/confounders was based on their clinical use as suggested by 7 worldwide recommendations for screening for total CVD risk [29]. The major classical CVD risk factors (i.e. those recommended by all 7 guidelines [29] i.e. age, gender, smoking, dyslipidemia, hypertension) were used in the models, as follows: model 1: unadjusted; model 2: adjusted for age and sex; model 3: model 2& smoking; model 4: model 3 & dyslipidemia; model 5: model 4 & hypertension. Additionally the next two most widely applied CVD risk factors i.e. body mass index for obesity and family history for premature coronary heart disease were introduced in model 6. Finally, in model 7 further adjustments were performed for the presence of blood pressure-lowering drugs, lipid-modifying drugs and glucose-lowering drugs. P< 0.05 was considered as the level of statistical significance. SPSS version 22.0 was used for all statistical analyses.

### Results

A total of 962 participants were included in the analysis (Table 1). Of them 226 had RA disease (time from diagnosis 123.7 (103.3–139.9) months), 133 had HIV infection (time from diagnosis 63.1 (52.2–73.9) months), 109 had T2DM, and 494 comprised the reference group. RA patients were predominantly women, older, less often dyslipidemic and were less often smokers compared to the RG. HIV infected patients were predominantly men, younger, less obese and more often smokers, but less often hypertensives and dyslipidemic, than the RG individuals. Diabetics were older, more obese and had more often hypertension and dyslipidemia than the RG.

### Presence of carotid and/or femoral subclinical atheromatosis


In the total cohort, 37.9% had at least one plaque at the femoral bed; 35.4% had at least one plaque at the carotid artery; 22.8% had plaques both at the femoral and the carotid beds; 50.1% had at least one plaque either at the carotid or the femoral artery or in both (Fig 1).

**Table 1. Descriptives of the population.** Continuous variables are presented as mean±standard deviation and categorical variables as percentage.

	RG(n = 494)	T2DM(n = 109)	HIV(n = 133)	RA(n = 226)
Age (years)	52.2±13.5	61.5±8.4	40.5±11.5	57.7±12.2
Male gender (%)	50.8	49.5	89.5	18.1
Hypertension (%)	59.7	78.9	15.8	51.8
Dyslipidemia (%)	37.7	66.1	26.3	28.8
Smoking				
Current (%)	33.6	38.5	52.6	29.2
Ex (%)	20.6	25.7	14.3	21.2
Family coronary heart disease (%)	14.8	16.7	15.9	14.3
Body mass index (kg/m <sup>2</sup> )	27.5±4.9	31.1±5.3	24.5±3.6	26.8±5.2
Drugs for diabetes (%)	0	94.5	0	0
Drugs for hypertension (%)	38.5	67.9	6.0	38.1
Drugs for dyslipidemia (%)	18.0	55.0	10.5	14.6

Abbreviations: RG: reference group, T2DM: type 2 diabetes mellitus, HIV: human immunodeficiency virus, RA: Rheumatoid arthritis.

doi:10.1371/journal.pone.0132307.t001




**Fig 1. Prevalence of subclinical atheromatosis assessed by plaques in femoral and carotid arteries in the studied adult cohort of 962 patients.**

doi:10.1371/journal.pone.0132307.g001

Among those participants with subclinical atheromatosis defined by the presence of any plaque in the carotid or the femoral bed (50.1% of the total cohort) (i) only femoral plaques, (ii) only carotid plaques, (iii) both femoral/carotid plaques were observed in: 29.9%, 24.7%, 45.4% in the total cohort; 24.2%, 32.9%, 42.9% in the RA subgroup; 24.9%, 22.6%, 52.5% in the HIV subgroup; 25.7%, 15.8%, 58.5% in T2DM and 35.4%, 23.7%, 40.9% in the RG (Fig 2).

### Probability of patients with T2DM, RA and HIV to have carotid plaques and femoral plaques compared to RG

After adjusting step by step (models 1 to 7, Table 2) for non-modifiable (age, sex, family history of premature coronary heart disease) and modifiable (smoking, hypertension, dyslipidemia, obesity) CVD risk factors, patients with RA and HIV infection had higher probability by 1.75 (1.17–2.63) and 2.04 (1.14–3.64) (odds ratio; 95% confidence interval), respectively, to have carotid plaques compared to RG (model 6, Table 2). In contrast, patients with RA and HIV infection did not have statistically significantly higher probabilities than RG to have femoral plaques (1.33 (0.87–2.02) and 0.70 (0.40–1.22), respectively (Table 2)). Patients with T2DM had higher probability by 1.67 (1.05–2.67) and 1.91 (1.16–3.16) than RG to have carotid plaques and femoral plaques, respectively (model 3); however after adjustment for the presence of dyslipidemia this association lost statistical significance (Table 2).



**Fig 2. Distribution (%) of plaques (i) only in carotid, (ii) only in femoral or (iii) in both carotid and femoral arteries in individuals with subclinical atherosclerosis associated with rheumatoid arthritis (RA), human immunodeficiency virus (HIV), and type 2 diabetes mellitus (T2DM) and in the reference group (RG).** (Abbreviations: DM: diabetes mellitus, HIV: human immunodeficiency virus, RA: Rheumatoid arthritis.)

doi:10.1371/journal.pone.0132307.g002

### The effect of classical CVD risk factors on carotid and femoral plaques

In multivariate regression analysis (model 6, [Table 3](#)), older age, male sex and smoking (current or ex-) were associated with higher probability for the presence of both carotid and femoral plaques; hypertension only with higher probability for carotid plaque presence and dyslipidemia only with higher probability for femoral plaque presence ([Table 3](#)).

In order to better adjust for age and gender we performed subanalysis using the final fully adjusted regression model (i.e. model 6) separate for each disease (i.e. for T2DM by excluding HIV subgroup and RA group; for HIV by excluding T2DM and RA; for RA by excluding T2DM and HIV). We excluded males in case of RA analysis and we excluded females in case of HIV analysis. In each subanalysis frequency matching for age between the reference group and each test group was performed. The results in each subanalysis regarding each test group (disease group) showed overall similar results to the main analysis (data not shown).

### Probability of patients with T2DM, RA and HIV to have “both carotid and femoral plaques” or “either carotid or femoral plaque” compared to RG

In order to test the probability of each disease to have a composite of “both carotid and femoral plaques” or “either carotid or femoral plaque” we repeated the regression analysis testing the odds ratio of having a composite of “both carotid and femoral plaques” versus “no plaque at all”, as well as, of having “either carotid or femoral Plaque” vs. “no plaque at all”. This analysis ([Table 4](#)) verified the differences between the main diseases (T2DM, HIV and RA) regarding

**Table 2. Probability of patients with Type 2 Diabetes Mellitus, Rheumatoid Arthritis and Human Immunodeficiency Virus Infection to have carotid plaque and femoral plaque (odds ratio (95% confidence interval)) in multivariate regression analysis using as comparator the reference group, before and after adjustment for potential confounders (model 1 to model 7).**

		Carotid plaque(n = 962)	Femoral plaque (n = 958)
<b>Model 1 (unadjusted)</b>	Type 2 Diabetes Mellitus	<b>3.14 (2.05–4.81)</b>	<b>3.25 (2.10–5.03)</b>
	Human immunodeficiency virus infection	0.67 (0.43–1.05)	0.54 (0.35–0.85)
	Rheumatoid Arthritis	<b>1.76 (1.27–2.42)</b>	1.12 (0.81–1.54)
<b>Model 2 (age &amp; sex)</b>	Type 2 Diabetes Mellitus	<b>1.84 (1.16–2.91)</b>	<b>2.14 (1.32–3.46)</b>
	Human immunodeficiency virus infection	1.52 (0.90–2.58)	0.74 (0.44–1.22)
	Rheumatoid Arthritis	<b>1.48 (1.02–2.16)</b>	<b>2.13 (1.32–3.46)</b>
<b>Model 3 (model 2 &amp; smoking)</b>	Type 2 Diabetes Mellitus	<b>1.67 (1.05–2.67)</b>	<b>1.91 (1.16–3.16) 5.03-</b>
	Human immunodeficiency virus infection	1.52 (0.89–2.62)	0.70 (0.41–1.18)
	Rheumatoid Arthritis	1.44 (0.98–2.12)	1.16 (0.78–1.73)
<b>Model 4 (model 3 &amp; dyslipidemia)</b>	Type 2 Diabetes Mellitus	1.58 (0.98–2.53)	1.62 (0.97–2.69)
	Human immunodeficiency virus infection	1.51 (0.88–2.60)	0.69 (0.40–1.18)
	Rheumatoid Arthritis	<b>1.51 (1.02–2.22)</b>	1.34 (0.89–2.01)
<b>Model 5 (model 4 &amp; hypertension)</b>	Type 2 Diabetes Mellitus	1.52 (0.94–2.44)	1.59 (0.96–2.64)
	Human immunodeficiency virus infection	<b>2.00 (1.14–3.51)</b>	0.75 (0.43–1.31)
	Rheumatoid Arthritis	<b>1.68 (1.12–2.50)</b>	1.39 (0.92–2.10)
<b>Model 6* (model 5 &amp; BMI, fCHD)</b>	Type 2 Diabetes Mellitus	1.56 (0.95–2.55)	1.58 (0.93–2.67)
	Human immunodeficiency virus infection	<b>2.04 (1.14–3.64)</b>	0.70 (0.40–1.22)
	Rheumatoid Arthritis	<b>1.75 (1.17–2.63)</b>	1.33 (0.87–2.02)

\* Further adjustment (model 7) for blood pressure lowering drugs, lipid modifying drugs and glucose lowering drugs did not modify the results.

BMI: body mass index, fCHD: family history of premature coronary heart disease

doi:10.1371/journal.pone.0132307.t002

**Table 3. Associations of classical and novel cardiovascular disease risk factors with the presence of carotid plaque and femoral plaque (odds ratio (95% confidence interval)) in multivariate regression analysis (model 6 of table 2).**

	Carotid plaque	Femoral plaque
Type 2 Diabetes Mellitus	1.56 (0.95–2.55)	1.58 (0.93–2.67)
Human immunodeficiency virus infection	<b>2.04 (1.14–3.64)</b>	0.70 (0.40–1.22)
Rheumatoid Arthritis	<b>1.75 (1.17–2.63)</b>	1.33 (0.87–2.02)
<b>Confounders in the adjusted model*</b>		
Age (for 1 year increase)	<b>1.09 (1.07–1.12)</b>	<b>4.84 (3.24–7.18)</b>
Male gender	<b>1.49 (1.03–2.14)</b>	<b>2.50 (1.62–3.85)</b>
Smoking		
Current (vs. non-smokers)	<b>3.02 (2.05–4.43)</b>	<b>4.84 (3.24–7.18)</b>
Ex (vs. non-smokers)	<b>1.78 (1.16–2.72)</b>	<b>2.50 (1.62–3.85)</b>
Hypertension	<b>2.10 (1.46–3.02)</b>	1.30 (0.90–1.88)
Dyslipidemia	1.29 (0.93–1.78)	<b>2.48 (1.78–3.56)</b>
Family history of coronary heart disease	1.41 (0.92–2.17)	1.05 (0.67–1.63)
Body mass index (for 1 Kg/m <sup>2</sup> increase)	1.00 (0.97–1.04)	0.99 (0.95–1.02)

\* Further adjustment for blood pressure lowering drugs, lipid modifying drugs and glucose lowering drugs did not modify the results.

doi:10.1371/journal.pone.0132307.t003

**Table 4. Associations of classical and novel cardiovascular disease risk factors with the presence of either “carotid plaque or femoral plaque” and “both carotid and femoral plaque” (odds ratio (95% confidence interval)) in multivariate regression analysis (model 6 of table 2).**

	Carotid or femoral plaque	Carotid & femoral plaques
Type 2 Diabetes Mellitus	1.18 (0.65–2.29)	<b>2.49 (1.25–4.96)</b>
Human immunodeficiency virus infection	0.69 (0.36–1.32)	1.60 (0.75–3.43)
Rheumatoid Arthritis	<b>1.95 (1.23–3.10)</b>	<b>1.90 (1.09–3.50)</b>
<b>Confounders in the adjusted model</b>		
Age (for 1 year increase)	+	+
Male gender	+	+
Smoking		
Current (vs. non-smokers)	+	+
Ex (vs. non-smokers)	+	+
Hypertension	+	+
Dyslipidemia	+	+
Family history of coronary heart disease	-	-
Body mass index (for 1 Kg/m <sup>2</sup> increase)	-	-

((+): in the model, (-): not in the model).

doi:10.1371/journal.pone.0132307.t004

their association with subclinical atheromatosis phenotypes and particularly showed that: (i) RA disease is associated with higher probability to develop “combined carotid & femoral plaques” as well as isolated atheromatosis (either at the carotid or the femoral bed); (ii) T2DM is associated with higher probability to develop “combined carotid & femoral plaques” but not isolated atheromatosis (either at the carotid or the femoral bed); (iii) most classical CV risk factors increased the odds ratio of having “isolated carotid or femoral plaque” as well as of “combined carotid and femoral plaques”.

## Discussion

Three are the novel findings of this study. First, variable but significant proportions of patients with high CVD risk-associated conditions such as RA, HIV infection and T2DM have subclinical atheromatosis only in the femoral arteries, irrespective of the underlying condition and the CVD risk factors. Variability is partly due to the accumulation of different classical CVD risk factors in each disease that—as the present data showed—differently affect femoral or carotid atheromatosis. For example, the vast majority of HIV patients, who are predominantly men and younger than RA and T2DM patients, consists of smokers. Second, chronic inflammatory conditions such as RA and HIV infection accelerate mainly carotid, rather than femoral subclinical atheromatosis. Third, a “two windows” (i.e. both femoral and carotid) screening approach for the detection of asymptomatic arterial plaque presence, would detect: (i) 25% of individuals with isolated femoral atheromatosis, and (ii) almost half of those who are at higher CVD risk due to presence of combined femoral and carotid plaques.

The main strengths of the present study lie to the fact that it is a single-center study including almost 1000 participants with or without classical and novel CVD risk factors such as RA and HIV infection, in whom subclinical atheromatosis at both the femoral and carotid bed was simultaneously assessed by the same operator.

In accordance with previous studies [1,2,3,30,31,32] we found that RA disease and HIV infection are associated with 1.8 and 2.0 times higher probability of subclinical atheromatosis

in the carotid bed, respectively. Data from patients undergoing endarterectomy have shown that carotid plaques had significantly increased proportions of macrophages/T cell infiltrates compared to femoral plaques, suggesting a more inflammatory phenotype in the carotid arterial bed [33]. Furthermore, carotid plaques predominantly displayed M1-activation markers, whereas femoral plaques M2-macrophages, the latter being associated with better plaque stability traits than the former [33]. These data imply that inflammation may play a more important role in the atheromatous process and plaque vulnerability in the carotid than the femoral bed. Considering the chronic inflammatory nature of both RA and HIV diseases, this hypothesis might explain our findings and should be further examined in RA and HIV patients, as well in other chronic autoimmune-mediated inflammatory diseases.

Several lines of evidence have previously shown that there are major differences regarding the atherogenic effect of classical CVD risk factors between the femoral and carotid bed [20,34,35,36]. We found no difference regarding the effect of age on the two arterial beds but men had higher relative probabilities of having femoral than carotid plaques, whereas inversely women had higher relative probabilities of having carotid than femoral plaques. Hypertension was also associated with higher relative probabilities to have carotid than femoral plaques whereas current smoking and dyslipidemia were associated with higher relative probabilities to have femoral than carotid plaques. Of note, in the present study the equal effect of T2DM on both arterial beds was predominantly mediated by the presence of dyslipidemia and not by glycaemia per se.

Previous studies have shown that differences between the two arterial beds exist also regarding the type of arterial remodelling process [37,38] as well as the morphological and histological traits of the plaques [33,39,40]. Even more the response to statin treatment differs between the two beds and is modulated by the presence of other CVD risk factors [41,42]. The clinical implications of all these differences have not been scrutinized yet but seem important. Subclinical femoral atheromatosis is independently associated with CVD incidence [43] and associates with the presence of CVD disease better than carotid atheromatosis [44,45,46,47]. This observation is related to emerging data suggesting that, compared to the other arteries (brachial, common carotid and ascending aorta) the femoral artery has an atherogenicity profile [48] and arterial wall elastic properties [49,50] that are closer to those of the coronary arterial bed. Therefore, it might be used as a better proxy of the coronary bed than the carotid artery [51]. Most importantly, by detecting patients with combined carotid and femoral subclinical atheromatosis it is feasible to identify the population at the highest CVD risk [18,19,46,52].

Because the existing CVD prediction scores may underestimate CVD risk in specific populations such as RA and HIV, international societies have proposed the incorporation of these novel CVD risk factors in the existing CVD risk prediction models in order to improve their discriminatory ability [53,54,55,56,57]. The performance of this strategy is under investigation. An alternative or complementary way to go forward is the addition of vascular biomarkers, such as subclinical plaque presence, in these models [4,12,13,14,15,16]. This approach may have additional advantages since subclinical atheromatosis integrates information related to all (novel and classical) CVD risk factors, and other yet poorly identified environmental and genetic factors [58]. In view of the above, physicians involved in primary CVD prevention of patients with novel CVD risk factors, such as RA disease or HIV infection, should be aware of the fact that, although these specific chronic inflammatory immune-mediated diseases may affect predominantly carotid atheromatosis, the accumulation of different comorbidities (such as smoking, dyslipidemia or hypertension) lead to acceleration of atheromatosis in other arterial beds.

The present study should be interpreted keeping in mind the following limitations. We acknowledge the fact that study groups differ in other aspects (age, gender) than disease (RA, DM, HIV) alone. Therefore, we paid considerable attention to statistical correction for

confounders, as described in the methods and as shown in Tables 2 and 3. Statistical correction using multivariate models is the method of choice in observational research, matching (e.g. for age and gender) is no advantage above statistical correction. The present analysis did not aim to investigate the specific mechanisms that lead to acceleration of atheromatosis in each one of the main studied pathologies (RA, HIV infection and T2DM) and did not investigate differences between them regarding plaque characteristics and stability. To what extent atheromatosis is caused by the dissimilar immune-inflammatory-genetic substrate of each disease or by disease-specific drugs or by other accumulated comorbidities is not clarified by this study. In the analysis we took into consideration all major and most underlying classical CVD risk factors [29] but not other emerging CVD risk factors (such as prothrombotic markers, C-reactive protein). However, these are disease-related characteristics and are incorporated in the effect of each chronic disease. The present study comprised of Caucasian people and the results may not be extrapolated to other ethnicities. Finally, in the present study we used as comparator a population referred to the Cardiovascular Laboratory for established or suspected hypertension and not a community-based general population. For this reason the relative impact of each disease on subclinical atheromatosis when compared to the general population may be underestimated.

## Conclusions and Perspectives

This study evaluated both the femoral and carotid subclinical atheromatosis and showed that novel CVD risk factors such as RA disease and HIV infection, but also classical CVD risk factors have a differential impact on atheromatosis of the carotid and femoral artery. However, an equally high prevalence of isolated femoral subclinical atheromatosis in all conditions was found due to the accumulation of different comorbidities in each disease, whereas almost 50% of those with subclinical atheromatosis might be potentially reclassified at higher CVD risk due to the combined presence of femoral and carotid atheromatosis. In order to better estimate the global burden of arterial atherosclerosis [17], our findings promote the concept of mapping [59] at multiple easily accessible arterial sites, as the right-way to go forward towards the individualization and optimization of CVD risk management. Prospective CVD event-driven studies should further evaluate this concept.

## Author Contributions

Conceived and designed the experiments: AP G. D. Kitas PPS JF. Performed the experiments: EZ AAA AA G. D. Konstantonis KM NT MP GD EA. Analyzed the data: AP G. D. Konstantonis G. D. Kitas PPS JF EA. Contributed reagents/materials/analysis tools: AP JF KM NT PPS MP GD. Wrote the paper: AP JF AAA EZ AA G. D. Konstantonis GD G. D. Kitas PPS KM NT MP EA.

## References

1. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. *Ann Intern Med.* 2006; 144:249–56. PMID: [16490910](#)
2. Stamatelopoulou KS, Kitas GD, Papamichael CM, Chrysoshoou E, Kyrkou K, Georgiopoulos G, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. *Arterioscler Thromb Vasc Biol.* 2009; 29:1702–8. doi: [10.1161/ATVBAHA.109.190108](#) PMID: [19608975](#)
3. Hulsen E, Mitchell J, Scally J, Villines TC. HIV positivity, protease inhibitor exposure and preclinical atheromatosis: a systematic review and meta-analysis of observational studies. *Heart* 2009; 95:1826–1835. doi: [10.1136/hrt.2009.177774](#) PMID: [19632982](#)
4. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J.* 2014 Mar 27. [Epub ahead of print].

5. Currier JS, Stein JH. HIV and Atherosclerosis: Moving From Associations to Mechanisms and Interventions. *Ann Intern Med.* 2014; 160:509–10. doi: [10.7326/M14-0378](https://doi.org/10.7326/M14-0378) PMID: [24687073](https://pubmed.ncbi.nlm.nih.gov/24687073/)
6. Post WS, Budoff M, Kingsley L, Palella FJ Jr, Witt MD, Li X, et al. Associations Between HIV Infection and Subclinical Coronary Atherosclerosis. *Ann Intern Med.* 2014; 160:458–67. doi: [10.7326/M13-1754](https://doi.org/10.7326/M13-1754) PMID: [24687069](https://pubmed.ncbi.nlm.nih.gov/24687069/)
7. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. *Ann Rheum Dis.* 2011; 70:8–14. doi: [10.1136/ard.2010.142133](https://doi.org/10.1136/ard.2010.142133) PMID: [21109513](https://pubmed.ncbi.nlm.nih.gov/21109513/)
8. Roman MJ, Kizer JR, Best LG, Howard BV, Shara NM, Devereux RB. Vascular biomarkers in the prediction of clinical cardiovascular disease. The Strong Heart Study. *Hypertension* 2012; 59:29–35. doi: [10.1161/HYPERTENSIONAHA.111.181925](https://doi.org/10.1161/HYPERTENSIONAHA.111.181925) PMID: [22068872](https://pubmed.ncbi.nlm.nih.gov/22068872/)
9. Held C, Hjemdahl P, Eriksson SV, Björkander I, Forslund L, Rehnqvist N. Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. *Eur Heart J.* 2001; 22:62–72. PMID: [11133211](https://pubmed.ncbi.nlm.nih.gov/11133211/)
10. Evans MR, Escalante A, Battafarano DF, Freeman GL, O' Leary DH, del Rincon I, et al. Carotid Atherosclerosis Predicts Incident Acute Coronary Syndromes in Rheumatoid Arthritis. *Arthritis Rheum.* 2011; 63:1211–1220.
11. Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. *Atherosclerosis.* 2011; 214:468–73. doi: [10.1016/j.atherosclerosis.2010.11.013](https://doi.org/10.1016/j.atherosclerosis.2010.11.013) PMID: [21130995](https://pubmed.ncbi.nlm.nih.gov/21130995/)
12. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2010; 56:e50–103. doi: [10.1016/j.jacc.2010.09.001](https://doi.org/10.1016/j.jacc.2010.09.001) PMID: [21144964](https://pubmed.ncbi.nlm.nih.gov/21144964/)
13. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Atherosclerosis.* 2011; 217 Suppl 1:S1–44. doi: [10.1016/j.atherosclerosis.2011.06.012](https://doi.org/10.1016/j.atherosclerosis.2011.06.012) PMID: [21723445](https://pubmed.ncbi.nlm.nih.gov/21723445/)
14. Zannad F, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmssen L, De Backer G, et al. Prevention of cardiovascular disease guided by total risk estimations—challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. *Eur J Prev Cardiol.* 2012; 19:1454–64. PMID: [23310961](https://pubmed.ncbi.nlm.nih.gov/23310961/)
15. Goff DC Jr, Lloyd-Jones DM, Bennett G, O'Donnell CJ, Coady S, Robinson J, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014; 63:2935–59.
16. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens.* 2013; 31:1281–357. doi: [10.1097/01.hjh.0000431740.32696.cc](https://doi.org/10.1097/01.hjh.0000431740.32696.cc) PMID: [23817082](https://pubmed.ncbi.nlm.nih.gov/23817082/)
17. Weir-McCall JR, Khan F, Lambert MA, Adamson CL, Gardner M, Gandy SJ, et al. Common carotid intima media thickness and ankle-brachial pressure index correlate with local but not global atheroma burden: a cross sectional study using whole body magnetic resonance angiography. *PLoS One.* 2014; 9:e99190. doi: [10.1371/journal.pone.0099190](https://doi.org/10.1371/journal.pone.0099190) PMID: [24933122](https://pubmed.ncbi.nlm.nih.gov/24933122/)
18. Belcaro G, Nicolaidis AN, Ramaswami G, Cesarone MR, De Sanctis M, Incandela L, et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study(1)). *Atherosclerosis.* 2001; 156:379–87. PMID: [11395035](https://pubmed.ncbi.nlm.nih.gov/11395035/)
19. Frerix M, Stegbauer J, Kreuter A, Weiner SM. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplex sonography study of carotid and femoral arteries and follow-up for cardiovascular events. *Arthritis Res Ther.* 2014; 16:R54. doi: [10.1186/ar4489](https://doi.org/10.1186/ar4489) PMID: [24548804](https://pubmed.ncbi.nlm.nih.gov/24548804/)
20. Salonen JT, Salonen R. Risk factors for carotid and femoral atherosclerosis in hypercholesterolaemic men. *J Intern Med.* 1994; 236:561–6. PMID: [7964434](https://pubmed.ncbi.nlm.nih.gov/7964434/)
21. Scuteri A, Najjar SS, Orru' M, Albai G, Strait J, Tarasov KV, et al. Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the SardiNIA Study. *Nutr Metab Cardiovasc Dis.* 2009; 19:532–41. doi: [10.1016/j.numecd.2008.11.004](https://doi.org/10.1016/j.numecd.2008.11.004) PMID: [19321325](https://pubmed.ncbi.nlm.nih.gov/19321325/)

22. Stamatelopoulos KS, Kitas GD, Papamichael CM, Kyrkou K, Zampeli E, Fragiadaki K, et al. Peripheral arterial disease in rheumatoid arthritis. *Atherosclerosis*. 2010; 212:305–9 doi: [10.1016/j.atherosclerosis.2010.05.007](https://doi.org/10.1016/j.atherosclerosis.2010.05.007) PMID: [20553683](https://pubmed.ncbi.nlm.nih.gov/20553683/)
23. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al. Premature atherosclerosis in HIV-infected individuals—focus on protease inhibitor therapy. *AIDS*. 2001; 15:329–34 PMID: [11273212](https://pubmed.ncbi.nlm.nih.gov/11273212/)
24. Williams R.. The Declaration of Helsinki and public health” *Bulletin of the World Health Organization*, 2008; 86: 650–652 PMID: [18797627](https://pubmed.ncbi.nlm.nih.gov/18797627/)
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.*; 31:315–24. PMID: [3358796](https://pubmed.ncbi.nlm.nih.gov/3358796/)
26. European Centre for Diseases Prevention and Control. HIV testing: Increasing uptake and effectiveness in the European Union. 2010. Evidence synthesis for Guidance on HIV testing. Stockholm: European Centre for Disease Prevention and Control.
27. American Diabetes Association, Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010; 33:S62–69. doi: [10.2337/dc10-S062](https://doi.org/10.2337/dc10-S062) PMID: [20042775](https://pubmed.ncbi.nlm.nih.gov/20042775/)
28. Roman MJ, Naqvi TZ, Gardin JM, Gerhard-Herman M, Jaff M, Mohler E et al. American society of echocardiography report. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. *Vasc Med*. 2006; 11:201–11 PMID: [17288128](https://pubmed.ncbi.nlm.nih.gov/17288128/)
29. Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, Steyerberg EW, et al. Systematic review of guidelines on cardiovascular risk assessment: Which recommendations should clinicians follow for a cardiovascular health check? *Arch Intern Med*. 2010; 170:27–40. doi: [10.1001/archinternmed.2009.434](https://doi.org/10.1001/archinternmed.2009.434) PMID: [20065196](https://pubmed.ncbi.nlm.nih.gov/20065196/)
30. Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. *Arterioscler Thromb Vasc Biol*. 2010; 30:1014–26. doi: [10.1161/ATVBAHA.109.198424](https://doi.org/10.1161/ATVBAHA.109.198424) PMID: [20150560](https://pubmed.ncbi.nlm.nih.gov/20150560/)
31. Jonsson SW, Backman C, Johnson O, Karp K, Lundström E, Sundqvist KG, et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. *J Rheumatol*. 2001; 28:2597–602. PMID: [11764203](https://pubmed.ncbi.nlm.nih.gov/11764203/)
32. Del Rincón I, Williams K, Stern MP, Freeman GL, O’Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. *Arthritis Rheum*. 2003; 48:1833–40. PMID: [12847676](https://pubmed.ncbi.nlm.nih.gov/12847676/)
33. Shaikh S, Brittenden J, Lahiri R, Brown PA, Thies F, Wilson HM. Macrophage subtypes in symptomatic carotid artery and femoral artery plaques. *Eur J Vasc Endovasc Surg*. 2012; 44:491–7. doi: [10.1016/j.ejvs.2012.08.005](https://doi.org/10.1016/j.ejvs.2012.08.005) PMID: [22975154](https://pubmed.ncbi.nlm.nih.gov/22975154/)
34. Fukudome Y, Fujii K, Abe I, Ohya Y, Fukuhara M, Kaseda S, et al. Ultrasonographic assessment of regional differences in atherosclerotic lesions in patients with hypertension, diabetes mellitus, or both. *Hypertens Res*. 1997; 20:175–81. PMID: [9328798](https://pubmed.ncbi.nlm.nih.gov/9328798/)
35. Langlois MR, Rietzschel ER, De Buyzere ML, De Bacquer D, Bekaert S, Blaton V, et al. Femoral plaques confound the association of circulating oxidized low-density lipoprotein with carotid atherosclerosis in a general population aged 35 to 55 years: the Asklepios Study. *ArteriosclerThrombVasc Biol*. 2008; 28:1563–8.
36. Panayiotou AG, Griffin M, Kouis P, Tyllis T, Georgiou N, Bond D, et al. Association between presence of the metabolic syndrome and its components with carotid intima-media thickness and carotid and femoral plaque area: a population study. *Diabetol Metab Syndr*. 2013; 5:44. doi: [10.1186/1758-5996-5-44](https://doi.org/10.1186/1758-5996-5-44) PMID: [23962225](https://pubmed.ncbi.nlm.nih.gov/23962225/)
37. Sass C, Herbeth B, Chapet O, Siest G, Visvikis S, Zannad F. Intima-media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas cohort: effect of age, sex, anthropometry and blood pressure. *J Hypertens*. 1998; 16: 1593–1602. PMID: [9856359](https://pubmed.ncbi.nlm.nih.gov/9856359/)
38. Bianda N, Di Valentino M, Périat D, Segatto JM, Oberson M, Moccetti M, et al. Progression of human carotid and femoral atherosclerosis: a prospective follow-up study by magnetic resonance vessel wall imaging. *Eur Heart J*. 2012; 33:230–7. doi: [10.1093/eurheartj/ehr332](https://doi.org/10.1093/eurheartj/ehr332) PMID: [21920966](https://pubmed.ncbi.nlm.nih.gov/21920966/)
39. Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. *Stroke*. 2007; 38:2698–705. PMID: [17761918](https://pubmed.ncbi.nlm.nih.gov/17761918/)
40. Herisson F, Heymann MF, Chétiveaux M, Charrier C, Battaglia S, Pilet P, et al. Carotid and femoral atherosclerotic plaques show different morphology. *Atherosclerosis*. 2011; 216:348–54. doi: [10.1016/j.atherosclerosis.2011.02.004](https://doi.org/10.1016/j.atherosclerosis.2011.02.004) PMID: [21367420](https://pubmed.ncbi.nlm.nih.gov/21367420/)

41. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, et al. A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. *Circulation*. 1995; 92:1758–64. PMID: [7671358](#)
42. de Sauvage Nolting PR, de Groot E, Zwinderman AH, Buirma RJ, Trip MD, Kastelein JJ. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. *Arch Intern Med*. 2003; 163:1837–41. PMID: [12912721](#)
43. Schmidt C(1), Fagerberg B, Hulthe J. Non-stenotic echolucent ultrasound-assessed femoral artery plaques are predictive for future cardiovascular events in middle-aged men. *Atherosclerosis*. 2005 Jul; 181(1):125–30. PMID: [15939063](#)
44. Kranjec I. Atherosclerotic burden in coronary and peripheral arteries in patients with first clinical manifestation of coronary artery disease. *J Cardiovasc Med (Hagerstown)*. 2011; 12:297–9.
45. Khoury Z, Schwartz R, Gottlieb S, Chenzbraun A, Stern S, Keren A. Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound. *Am J Cardiol*. 1997 Dec 1; 80(11):1429–33. PMID: [9399716](#)
46. Griffin M, Nicolaides A, Tyllis T, Georgiou N, Martin RM, Bond D, et al. Carotid and femoral arterial wall changes and the prevalence of clinical cardiovascular disease. *Vasc Med* 2009; 14:227. doi: [10.1177/1358863X08101542](#) PMID: [19651672](#)
47. Dalager S, Falk E, Kristensen IB, Paaske WP. Plaque in superficial femoral arteries indicates generalized atherosclerosis and vulnerability to coronary death: an autopsy study. *J Vasc Surg*. 2008; 47:296–302. doi: [10.1016/j.jvs.2007.10.037](#) PMID: [18241752](#)
48. Pasterkamp G, Schoneveld AH, van der Wal AC, Hijnen DJ, van Wolveren WJ, Plomp S, et al. Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. *Arterioscler Thromb Vasc Biol*. 1999; 19:54–8. PMID: [9888866](#)
49. Safar ME, O'Rourke MF. *Arterial stiffness in hypertension*. Elsevier: Amsterdam, 2006.
50. Maher E, Early M, Creane A, Lally C, Kelly DJ. Site specific inelasticity of arterial tissue. *J Biomech*. 2012; 8:1393–1399.
51. van Sloten TT, Schram MT, van den Hurk K, Dekker JM, Nijpels G, Henry RM, et al. Local stiffness of the carotid and femoral artery is associated with incident cardiovascular events and all-cause mortality—The Hoorn Study. *J Am Coll Cardiol*. 2014; 63:1739–47. doi: [10.1016/j.jacc.2013.12.041](#) PMID: [24583306](#)
52. Lamina C, Meisinger C, Heid IM, Löwel H, Rantner B, Koenig W, et al. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. *Eur Heart J*. 2006; 27:2580–7. PMID: [16952925](#)
53. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Ann Rheum Dis*. 2010; 69:325–31. doi: [10.1136/ard.2009.113696](#) PMID: [19773290](#)
54. Kawai VK1, Chung CP, Solus JF, Oeser A, Raggi P, Stein CM. The ability of the 2013 ACC/AHA cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores. *Arthritis Rheumatol*. 2014; [Epub ahead of print]
55. Friis-Møller N, Thiébaud R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil*. 2010; 17:491–501.
56. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. *JAMA Intern Med*. 2013; 173:614–22. doi: [10.1001/jamainternmed.2013.3728](#) PMID: [23459863](#)
57. Arts EE, Popa C, Den Broeder AA, Semb AG, Toms T, Kitis GD, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. *Ann Rheum Dis*. 2014 Jan 3. doi: [10.1136/annrheumdis-2013-204024](#)
58. Maeno T, Koyama H, Tahara H, Komatsu M, Emoto M, Shoji T, et al. The 807T allele in alpha2 integrin is protective against atherosclerotic arterial wall thickening and the occurrence of plaque in patients with type 2 diabetes. *Diabetes*. 2002; 51:1523–8. PMID: [11978651](#)
59. Protogerou AD, Papaioannou TG, Vlachopoulos C. Arterial stiffness mapping: a better navigation to lthaca? *J Am Coll Cardiol*. 2014; 63:1748–50. doi: [10.1016/j.jacc.2014.01.044](#) PMID: [24583298](#)